Lv51
830 积分 2021-02-26 加入
Long-term survival outcomes of salvage [225Ac]Ac-PSMA-617 targeted alpha therapy in patients with PSMA-expressing end-stage metastatic castration-resistant prostate cancer: a real-world study
5小时前
已完结
The Molecular Biology of Midgut Neuroendocrine Neoplasms
1个月前
已完结
Neuroendocrine neoplasms of the lung and gastrointestinal system: convergent biology and a path to better therapies
4个月前
已完结
Whole-body single photon emission computed tomography/computed tomography for assessment of oncological bone disease – is an extended field of view (from vertex to toes) of clinical value?
5个月前
已完结
Salivary toxicity from PSMA-targeted radiopharmaceuticals: What we have learned and where we are going
5个月前
已完结
[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial
6个月前
已完结
Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial
6个月前
已完结
Actinium-225 targeted alpha particle therapy for prostate cancer
6个月前
已完结
Diagnostic Performance and Safety of Positron Emission Tomography with 18F-rhPSMA-7.3 in Patients with Newly Diagnosed Unfavourable Intermediate- to Very-high-risk Prostate Cancer: Results from a Phase 3, Prospective, Multicentre Study (LIGHTHOUSE)
6个月前
已完结
Clinical summary of fibroblast activation protein inhibitor-based radiopharmaceuticals: cancer and beyond
8个月前
已完结
皖公网安备34019202002308
